Please check with your physician for additional protocols and/or information.
1. E1411: Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+Bendamustine Followed by Rituximab Consolidation; Arm B = Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation, Arm C = Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation or Arm D = Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide+Rituximab Consolidation
In step 1, the purpose of this study is to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on you and your lymphoma compared to rituximab plus bendamustine alone.
In step 2, the purpose is to find out what effects, good and bad, continuing treatment after step 1 with lenalidomide plus rituximab has on you and your lymphoma compared to continuing treatment with rituximab alone.
2. E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP) has on you and your cancer. Everybody in this study will receive standard chemotherapy. In addition to standard chemotherapy randomly chosen half of the patients will receive a medication called lenalidomide. Adding lenalidomide to the standard chemotherapy RCHOP is considered experimental in diffuse large B cell lymphoma, and is not FDA approved. There is NO placebo (“sugar pill”) in this study, and everybody selected will receive an active medication.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133.